Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Valve-Specific Comparative Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists After Surgical Valve Procedures in Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Cardiology in review·2026
Same author

Gα<sub>o/z</sub>-biased coupling profile of the dopamine D3 receptor.

Communications biology·2026
Same author

Device-based therapies for cardiorenal syndrome: A comprehensive, mechanism-driven framework for next-generation decongestion.

European journal of internal medicine·2026
Same author

Progressive correction of auditory hair cell orientation in the absence of core planar cell polarity and GPR156 signaling.

Development (Cambridge, England)·2026
Same author

Efficacy of GLP-1 Receptor agonists in treating Obstructive sleep apnea: A systematic review and meta-analysis of cardiometabolic and respiratory outcomes.

Sleep & breathing = Schlaf & Atmung·2026
Same author

Treatment of left ventricular dysfunction during cancer therapy: a comprehensive review.

Drugs in context·2026

相关实验视频

Updated: May 2, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

8.4K

托尔瓦普坦的作用,一个血管压素对手,在住院患者的心力衰竭恶化:一个随机对照试验.

Mihai Gheorghiade1, Wendy A Gattis, Christopher M O'Connor

  • 1Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA. m-gheorghiade@northwestern.edu

JAMA
|April 29, 2004
PubMed
概括

托尔瓦普坦在住院的心力衰竭患者中有效降低了体重,没有对电解质或功能产生不良影响. 需要进一步的研究来证实其对恶化心力衰竭事件的影响.

更多相关视频

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

8.9K
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
07:59

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Published on: July 28, 2018

10.9K

相关实验视频

Last Updated: May 2, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

8.4K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

8.9K
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
07:59

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Published on: July 28, 2018

10.9K

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 美国每年近100万人因心力衰竭住院,与系统性拥堵有关.
  • 利尿剂是一种常见的治疗方法,可以导致电解质失衡和脏问题.
  • 托尔瓦普坦是一种血管压素抗剂,为心力衰竭中流体管理提供了潜在的替代方案.

研究的目的:

  • 评估托尔瓦普坦在住院心力衰竭患者的短期和中期影响.
  • 评估托尔瓦普坦在控制系统性拥堵方面的疗效.

主要方法:

  • 一个随机的,双盲的,安慰剂对照的第二阶段试验,涉及319名心力衰竭和喷射率<40%的患者.
  • 患者接受了口服托尔瓦普坦 (30,60或90毫克/天) 或安慰剂,并接受标准治疗长达60天.
  • 主要结局包括24小时后体重的变化和60天后心力衰竭的恶化.

主要成果:

  • 与安慰剂相比,托尔瓦普坦在所有剂量中在24小时内显著降低了体重 (P ≤ .008).
  • 没有观察到对心率,血压,电解质 (低血糖) 或功能有重大不良影响.
  • 在托尔瓦普坦和安慰剂组之间60天内心力衰竭事件恶化没有差异 (P = .88).
  • 后期分析表明,在托尔瓦普坦患者中,功能障碍或严重拥堵的60天死亡率降低.

结论:

  • 托尔瓦普坦在添加到标准治疗时,在住院心力衰竭患者的全身拥堵管理方面显示出前景.
  • 它在不损害功能或电解质的情况下降低液体过载的能力是其关键好处.